These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34890866)

  • 1. Differential serum lipid distribution in IPAH and CHD-PAH patients.
    Chen J; Rathinasabapathy A; Luo J; Yang X; Luo P; Chen Y; Li Z; Li J
    Respir Med; 2022 Jan; 191():106711. PubMed ID: 34890866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of cardiopulmonary exercise testing in comparing cardio-pulmonary function among patients with three kinds of pulmonary artery hypertension].
    Zhao Q; Liu Z; Ma X; Zhao Z; Luo Q; Gu Q; Xiong C; Zhang H; Wang Y
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3598-601. PubMed ID: 26813372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 4. CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension.
    Tomaszewski M; Małkowska P; Sierawska O; Hrynkiewicz R; Mroczek E; Darocha S; Hymos A; Błaszczak P; Grywalska E; Niedźwiedzka-Rystwej P
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of changes in NT-proBNP, hsTnT and uric acid levels with haemodynamic changes after targeted medical therapies in patients with idiopathic pulmonary arterial hypertension.
    Li WT; Wu CW; Liu JM
    Cardiovasc J Afr; 2022 Jan-Feb 23; 33(1):10-14. PubMed ID: 34851353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of high risk factors for patient death and its clinical characteristics on pregnancy associated with pulmonary arterial hypertension].
    Bao Z; Zhang J; Yang D; Xu X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):495-500. PubMed ID: 25327730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).
    Barst RJ; Ivy DD; Foreman AJ; McGoon MD; Rosenzweig EB
    Am J Cardiol; 2014 Jan; 113(1):147-55. PubMed ID: 24176071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
    Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
    BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of relationship between P wave dispersion and diagnosis of pulmonary arterial hypertension and risk stratification.
    Luo J; Sun J; Xu L; Chen J; Chen Y; Chen W; Qiu H; Luo X; Chen S; Li J
    J Electrocardiol; 2023; 81():94-100. PubMed ID: 37657302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in right ventricular function and response to targeted therapy between patients with IPAH and PAH-CHD.
    Zhu T; Wu P; Tan Z; Jin Q; Chen Y; Li L; Chen Z; Tang Y; Li J; Fang Z
    Front Pharmacol; 2023; 14():1124746. PubMed ID: 36860300
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential biventricular adaption to pulmonary vascular disease in patients with idiopathic/heritable and congenital heart disease: a prospective cardiac magnetic resonance and invasive study.
    Xu Z; Dou R; Zhou Z; Zhang H; Zhang C; Li Q; Xu L; Gu H
    Eur Heart J Cardiovasc Imaging; 2023 Oct; 24(11):1528-1535. PubMed ID: 37201191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Classification, diagnosis and treatment status of pulmonary hypertension from 2012 to 2019: a single center study in Yunnan province].
    Feng XL; Lu YB; Yang D; Xue Q; Zhang JL; Lin CR; Gan P; Zhang WH; Guang XF; Dai HL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Nov; 51(11):1188-1193. PubMed ID: 37963755
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension.
    Daly CM; Griffiths M; Simpson CE; Yang J; Damico RL; Vaidya RD; Williams M; Brandal S; Jone PN; Polsen C; Ivy DD; Austin ED; Nichols WC; Pauciulo MW; Lutz K; Nies MK; Rosenzweig EB; Hirsch R; Yung D; Everett AD
    J Am Heart Assoc; 2021 Oct; 10(20):e021409. PubMed ID: 34622662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Chinese Children: Similarities, Differences, and Prognostic Factors.
    Gu L; Li YY; Gu L; Xie L; Liu HM
    Front Pediatr; 2020; 8():106. PubMed ID: 32296664
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical characteristics of 195 Chinese patients with WHO Class I pulmonary hypertension].
    Zhang G; Shang X; Deng X; Zhou H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Dec; 42(12):1001-5. PubMed ID: 25623345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease.
    Latus H; Wagner I; Ostermayer S; Kerst G; Kreuder J; Schranz D; Apitz C
    Pediatr Cardiol; 2017 Oct; 38(7):1342-1349. PubMed ID: 28681131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics.
    Jin N; Yu M; Du X; Wu Z; Zhai C; Pan H; Gu J; Xie B
    BMC Cardiovasc Disord; 2023 Mar; 23(1):167. PubMed ID: 36991345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease.
    Luna-Lopez R; Segura de la Cal T; Sarnago Cebada F; Martin de Miguel I; Hinojosa W; Cruz-Utrilla A; Velazquez MT; Delgado JF; Mendoza A; Arribas Ynsaurriaga F; Escribano-Subías P
    Heart; 2024 Feb; 110(5):346-352. PubMed ID: 37903556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment goals of pulmonary hypertension.
    McLaughlin VV; Gaine SP; Howard LS; Leuchte HH; Mathier MA; Mehta S; Palazzini M; Park MH; Tapson VF; Sitbon O
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D73-81. PubMed ID: 24355644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.